196 related articles for article (PubMed ID: 30293336)
41. Epidemiology of chronic inflammatory neuropathies in southeast England.
Mahdi-Rogers M; Hughes RA
Eur J Neurol; 2014; 21(1):28-33. PubMed ID: 23679015
[TBL] [Abstract][Full Text] [Related]
42. Clinical Characteristics and Treatment Response of Chronic Inflammatory Demyelinating Polyradiculoneuropathy.
Suanprasert N; Hanchaiphiboolkul S
J Med Assoc Thai; 2017 Mar; 100(3):262-9. PubMed ID: 29911781
[TBL] [Abstract][Full Text] [Related]
43. Fibronectin connecting segment-1 peptide inhibits pathogenic leukocyte trafficking and inflammatory demyelination in experimental models of chronic inflammatory demyelinating polyradiculoneuropathy.
Dong C; Greathouse KM; Beacham RL; Palladino SP; Helton ES; Ubogu EE
Exp Neurol; 2017 Jun; 292():35-45. PubMed ID: 28215575
[TBL] [Abstract][Full Text] [Related]
44. Chronic inflammatory demyelinating polyradiculoneuropathy: a role for haematopoietic stem cell transplantation?
Kazmi MA; Mahdi-Rogers M; Sanvito L
Autoimmunity; 2008 Dec; 41(8):611-5. PubMed ID: 18958756
[TBL] [Abstract][Full Text] [Related]
45. Rituximab in chronic inflammatory demyelinating polyneuropathy associated with diabetes mellitus.
Münch C; Anagnostou P; Meyer R; Haas J
J Neurol Sci; 2007 May; 256(1-2):100-2. PubMed ID: 17382963
[TBL] [Abstract][Full Text] [Related]
46. Chronic inflammatory demyelinating polyradiculoneuropathy: update on clinical features, phenotypes and treatment options.
Eftimov F; van Schaik I
Curr Opin Neurol; 2013 Oct; 26(5):496-502. PubMed ID: 23852276
[TBL] [Abstract][Full Text] [Related]
47. Chronic inflammatory demyelinating polyradiculoneuropathy in solid organ transplant recipients: a prospective study.
Echaniz-Laguna A; de Séze J; Chanson JB
J Neurol Neurosurg Psychiatry; 2012 Jul; 83(7):699-705. PubMed ID: 22577230
[TBL] [Abstract][Full Text] [Related]
48. Chronic inflammatory demyelinating polyradiculoneuropathy and variants: where we are and where we should go.
Nobile-Orazio E
J Peripher Nerv Syst; 2014 Mar; 19(1):2-13. PubMed ID: 24612201
[TBL] [Abstract][Full Text] [Related]
49. Risk factors for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): antecedent events, lifestyle and dietary habits. Data from the Italian CIDP Database.
Doneddu PE; Bianchi E; Cocito D; Manganelli F; Fazio R; Filosto M; Mazzeo A; Cosentino G; Cortese A; Jann S; Clerici AM; Antonini G; Siciliano G; Luigetti M; Marfia GA; Briani C; Lauria G; Rosso T; Cavaletti G; Carpo M; Benedetti L; Beghi E; Liberatore G; Santoro L; Peci E; Tronci S; Cotti Piccinelli S; Toscano A; Piccolo L; Verrengia EP; Leonardi L; Schirinzi E; Mataluni G; Ruiz M; Dacci P; Nobile-Orazio E;
Eur J Neurol; 2020 Jan; 27(1):136-143. PubMed ID: 31325350
[TBL] [Abstract][Full Text] [Related]
50. Chronic inflammatory demyelinating polyradiculoneuropathy: search for factors associated with treatment dependence or successful withdrawal.
Rabin M; Mutlu G; Stojkovic T; Maisonobe T; Lenglet T; Fournier E; Bouche P; Léger JM; Viala K
J Neurol Neurosurg Psychiatry; 2014 Aug; 85(8):901-6. PubMed ID: 24309269
[TBL] [Abstract][Full Text] [Related]
51. Segmental evaluation of the peripheral nerve using tibial nerve SEPs for the diagnosis of CIDP.
Tsukamoto H; Sonoo M; Shimizu T
Clin Neurophysiol; 2010 Jan; 121(1):77-84. PubMed ID: 19850515
[TBL] [Abstract][Full Text] [Related]
52. Chronic inflammatory demyelinating polyradiculoneuropathy presenting as cauda equina syndrome in a diabetic.
Lai WW; Ubogu EE
J Neurol Sci; 2007 Sep; 260(1-2):267-70. PubMed ID: 17521674
[TBL] [Abstract][Full Text] [Related]
53. Elevated Vibration Perception Thresholds in CIDP Patients Indicate More Severe Neuropathy and Lower Treatment Response Rates.
Abraham A; Albulaihe H; Alabdali M; Qrimli M; Breiner A; Barnett C; Katzberg HD; Lovblom LE; Perkins BA; Bril V
PLoS One; 2015; 10(11):e0139689. PubMed ID: 26545096
[TBL] [Abstract][Full Text] [Related]
54. CIDP in a HIV endemic population: A prospective case series from Johannesburg, South Africa.
Mochan A; Anderson D; Modi G
J Neurol Sci; 2016 Apr; 363():39-42. PubMed ID: 27000218
[TBL] [Abstract][Full Text] [Related]
55. Intravenous immunoglobulin is effective in patients with diabetes and with chronic inflammatory demyelinating polyneuropathy: long term follow-up.
Jann S; Bramerio MA; Facchetti D; Sterzi R
J Neurol Neurosurg Psychiatry; 2009 Jan; 80(1):70-3. PubMed ID: 18768571
[TBL] [Abstract][Full Text] [Related]
56. Challenges in the treatment of chronic inflammatory demyelinating polyradiculoneuropathy.
Guimarães-Costa R; Iancu Ferfoglia R; Viala K; Léger JM
Rev Neurol (Paris); 2014 Oct; 170(10):595-601. PubMed ID: 25200479
[TBL] [Abstract][Full Text] [Related]
57. [Biochemical features of chronic inflammatory demyelinating polyradiculoneuropathy].
Antoine JC
Rev Neurol (Paris); 2006 Apr; 162(4):533-8. PubMed ID: 16585917
[TBL] [Abstract][Full Text] [Related]
58. Treatment of chronic immune-mediated neuropathies: chronic inflammatory demyelinating polyradiculoneuropathy, multifocal motor neuropathy, and the Lewis-Sumner syndrome.
Sederholm BH
Semin Neurol; 2010 Sep; 30(4):443-56. PubMed ID: 20941678
[TBL] [Abstract][Full Text] [Related]
59. Chronic inflammatory demyelinating polyneuropathy with anti-NF155 IgG4 in China.
Zhang X; Zheng P; Devaux JJ; Wang Y; Liu C; Li J; Guo S; Song Y; Wang Q; Feng X; Wang Y
J Neuroimmunol; 2019 Dec; 337():577074. PubMed ID: 31693967
[TBL] [Abstract][Full Text] [Related]
60. Fatigue as the main presenting symptom of chronic inflammatory demyelinating polyradiculoneuropathy: a study of 11 cases.
Boukhris S; Magy L; Gallouedec G; Khalil M; Couratier P; Gil J; Vallat JM
J Peripher Nerv Syst; 2005 Sep; 10(3):329-37. PubMed ID: 16221292
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
